- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Cytoxan, Cytoxan Lyophilized, Neosar
Synonyms :
Class :
Class: anti cancer drugs, Sub class: nitrogen mustards
Dosage forms and strengths:
Tablet
Powder for injection
intermittent therapy:
40 - 50
mg/kg
Intravenous (IV)
dose/day
2 - 5
days
Dose Adjustments
continuous daily therapy: 60-120 mg/m² IV once a day intermittent therapy: 400-1000 mg/m² orally once a day for 4-5 days continuous daily therapy: 50-100 mg/m² orally once a day
6
mg/m^2
Intravenous (IV)
with other anti-cancer agents
Dosage forms and strengths:
Tablet
Powder for injection
intermittent therapy:
40 - 50
mg/kg
Intravenous (IV)
2 - 5
days
Dose Adjustments
continuous daily therapy: 60-120 mg/m² IV once a day intermittent therapy: 400-1000 mg/m² orally once a day for 4-5 days continuous daily therapy: 50-100 mg/m² orally once a day
it may reduce the therapeutic effect of covid-19 vaccines
may decrease the therapeutic effect of COVID-19 vaccine
cyclophosphamide effect of action increased by affecting enzyme CYP3A4 metabolism.
cyclophosphamide effect of action decreased by affecting enzyme CYP3A4 metabolism.
when both the drugs combine the effect of both drugs increases by immunosuppressive effects
when both the drugs combine the effect of both drugs increases by immunosuppressive effects
when both the drugs combine the effect of both drugs increases by immunosuppressive effects
the effect of both drug toxicity increases by synergism
cyclophosphamide effect of action decreased by affecting enzyme CYP3A4 metabolism.
the toxicity of cyclophosphamide increases by decreasing renal clearance.
cyclophosphamide effect of action decreased by affecting enzyme CYP3A4 metabolism.
influenza virus vaccine quadrivalent
the influenza virus vaccine quadrivalent, adjuvanted effect of action decreases by antagonism.
influenza virus vaccine trivalent adjuvanted
the influenza virus vaccine trivalent, adjuvanted effect of action decreases by antagonism.
when both the drugs combine the effect of both drugs increases by immunosuppressive effects
cyclophosphamide effect of action increased by affecting enzyme CYP3A4 metabolism.
the toxicity of cyclophasphamide increases by palifermin.
both drug toxicity increases by other.
when both the drugs combine the effect of both drugs increases by immunosuppressive effects
when both the drugs combine the effect of both drugs increases by immunosuppressive effects
cyclophosphamide effect of action increased by affecting enzyme CYP3A4 metabolism.
cyclophosphamide effect of action increased by affecting enzyme CYP3A4 metabolism.
may increase toxicity of the drug by decreasing the renal clearance
both drug toxicity increases by synergism action.
the toxicity of cyclophosphamide increases by decreasing metabolism.
unknown mechanism, but effects of antithrombin III increases.
the argatroban effects of action increases.
cyclophosphamide effect of action increased by affecting enzyme CYP3A4 metabolism.
cyclophosphamide effect of action increased by affecting enzyme CYP3A4 metabolism.
cyclophosphamide effect of action increased by affecting enzyme CYP3A4 metabolism.
cyclophosphamide effect of action increased by affecting enzyme CYP3A4 metabolism.
when both the drugs combine the effect of both drugs increases by immunosuppressive effects and increase the risk of infection.
cyclophosphamide effect of action decreased by affecting enzyme CYP3A4 metabolism
both drug toxicity increases by synergism action
the effects of bivalirudin increases by unknown function.
both drug toxicity increases by synergism action
cyclophosphamide effect of action decreased by affecting enzyme CYP3A4 metabolism
cyclophosphamide effect of action decreased by affecting enzyme CYP3A4 metabolism
cyclophosphamide effect of action decreased by affecting enzyme CYP3A4 metabolism
both drug toxicity increases by synergism action
both drug toxicity increases by synergism action
cyclophosphamide effect of action decreased by affecting enzyme CYP3A4 metabolism
both drug toxicity increases by synergism action
when both the drugs combine the effect of vaccine decreases by immunosuppressive effects and increase the risk of infection.
both drug toxicity increases by synergism action
cyclophosphamide effect of action decreased by affecting enzyme CYP3A4 metabolism
both drug toxicity increases by synergism action
cyclophosphamide effect of action increased by affecting enzyme CYP3A4 metabolism.
when both the drugs combine the effect of vaccine decreases by immunosuppressive effects and increase the risk of infection.
the effect of action of digoxin decreases by inhibiting GI absorption.
both drug toxicity increases by synergism action
cyclophosphamide effect of action increased by affecting enzyme CYP3A4 metabolism.
cyclophosphamide effect of action increased by affecting enzyme CYP3A4 metabolism.
when both the drugs combine the effect of both drugs increases by immunosuppressive effects and increase the risk of infection.
cyclophosphamide: they may increase the toxic effect when combined with thiazides
cyclophosphamide: they may increase the toxic effect when combined with thiazides
cyclophosphamide: they may increase the toxic effect when combined with thiazides
cyclophosphamide: they may increase the toxic effect when combined with thiazides
It may enhance the effects when combined with tasimelteon by affecting CYP3A4 metabolism
Combining cyclophosphamide with pranlukast may cause a reduction in the cyclophosphamide’s metabolism
Combining tegafur with cyclophosphamide can reduce tegafur’s metabolism
By synergism effects, the toxicity of the other drug increases.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when thiotepa and cyclophosphamide combine, the toxicity of both drugs increases by synergism
when both the drugs are combined, the risk or severity of adverse effects increases
enhance cardiac toxicity
enhance cardiac toxicity
may increase the toxic effect of granulocyte colony stimulating factors
cyclophosphamide effect of action increased by affecting enzyme CYP3A4 metabolism.
ruxolitinib effect of action increased by affecting enzyme CYP3A4 metabolism.
cyclophosphamide can impact the hepatic/intestinal enzyme CYP3A4 metabolism, leading to an elevation in the level or potency of intranasal midazolam
Adverse drug reactions:
Frequency defined
>10%
1-10%
Frequency Not Defined
Pregnancy and Lactation:
Pregnancy:
Lactation:
Pregnancy Categories:
Cyclophosphamide is used to treat various kinds of cancer by retarding or cessing the growth of the cancer cells.
It decreases the immune response of your body to various diseases.
It also treats certain kidney diseases in children that the other medications have not effectively treated.
The dosage is strictly based on your doctor’s prescription.
You must tell your doctor if you are taking previous medications, either OTC or prescription drugs, to counteract any allergic reaction or contraindication.
Since the drug is teratogenic, pregnant females are not allowed to take the same.
The dust of the tablet and capsule is also harmful to the lungs and gut hence not being inhaled by expecting or gestating females.
Side effects may occur during the treatment, like vomiting, nausea, loss of appetite, redness in the eyes, flushing, pain at injection, abdominal pain, trouble sleeping, darkening of nails, and temporary hair loss.
If you miss the dose, tell your healthcare provider to reschedule it.
Store the medication at room temperature in a dry place.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
